Wire · opportunities
Lilly cans early obesity drug after 'high bar' not met
◆ Sectors
Drug Discovery
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Eli Lilly has discontinued development of an early-stage experimental obesity drug after failing to meet a 'high bar' of efficacy or safety in trials, reflecting stringent standards in obesity drug development.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
Obesity drug developers now face yet higher efficacy and safety expectations. You need to reassess your drug candidates’ profiles quickly or risk failing late-stage trials and wasted resources.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics
Drug Discoveryobesity-drugsdrug-developmentclinical-trialspharmaLilly